ZaBeCor forms unit to devise treatments for blood, lymphatic cancers

09/25/2008 | Philadelphia Inquirer, The

ZaBeCor Pharmaceuticals has established Biothorpe Pharmaceuticals, a unit that will develop molecular technologies aimed at treating cancers such as acute myelogenous leukemia and B-cell lymphoma. The biotech subsidiary will concentrate its efforts on Syk kinase, a substance that has been found to play a role in the growth of malignant cells in various cancers.

View Full Article in:

Philadelphia Inquirer, The

Published in Brief:

SmartBrief Job Listings for Health Care